{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:25:50Z","timestamp":1789647950183,"version":"4.0.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100011198","name":"State Key Laboratory of Drug Research, Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["SKLSIM-F-20244V"],"award-info":[{"award-number":["SKLSIM-F-20244V"]}],"id":[{"id":"10.13039\/501100011198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40121-026-01341-4","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T01:28:54Z","timestamp":1775784534000},"page":"1203-1248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antibiotic Pharmacokinetics and Prostate Penetration in Bacterial Prostatitis: A Systematic Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Rui","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwen","family":"Nian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1252-7961","authenticated-orcid":false,"given":"Zhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"1341_CR1","first-page":"2763","volume":"205","author":"F Lupo","year":"2020","unstructured":"Lupo F, Rousseau M, Canton T, Ingersoll MA. The immune system fails to mount a protective response to Gram-positive or Gram-negative bacterial prostatitis. J Invest Med. 2020;205:2763\u201377.","journal-title":"J Invest Med"},{"key":"1341_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14070681","author":"L Gisbert","year":"2025","unstructured":"Gisbert L, Dietl B, Xercavins M, Mateu A, L\u00f3pez M, Mart\u00ednez-Urrea A, et\u00a0al. Clinical outcomes of Escherichia coli acute bacterial prostatitis: a comparative study of oral sequential therapy with \u03b2-lactam versus quinolone antibiotics. Antibiotics Basel. 2025. https:\/\/doi.org\/10.3390\/antibiotics14070681.","journal-title":"Antibiotics Basel"},{"key":"1341_CR3","first-page":"45","volume":"110","author":"JC Lam","year":"2024","unstructured":"Lam JC, Stokes W. Acute and chronic prostatitis. Am Fam Physician. 2024;110:45\u201351.","journal-title":"Am Fam Physician"},{"key":"1341_CR4","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jiac.2021.06.001","volume":"27","author":"M Matsumoto","year":"2021","unstructured":"Matsumoto M, Yamamoto S. AAUS guideline for acute bacterial prostatitis 2021. J Infect Chemother. 2021;27:1277\u201383.","journal-title":"J Infect Chemother"},{"key":"1341_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmicom.2025.105156","volume":"3","author":"L Cordes Louren\u00e7o","year":"2026","unstructured":"Cordes Louren\u00e7o L, Wilmsen M, Calin R, Gupta K, Lafaurie M, Lavergne V, et\u00a0al. Evidence for antibiotic durations in chronic bacterial prostatitis: a systematic review. CMI Commun. 2026;3:105156.","journal-title":"CMI Commun"},{"key":"1341_CR6","unstructured":"Mou Y, Cao M, Zhang D. The blood\u2013prostate barrier: an obstacle to drug delivery into the prostate. Current drug delivery. 2023."},{"key":"1341_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1439-0272.2003.tb00868.x","volume":"35","author":"KG Naber","year":"2003","unstructured":"Naber KG, S\u00f6rgel F. Antibiotic therapy\u2014rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia. 2003;35:331\u20135.","journal-title":"Andrologia"},{"key":"1341_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000074526","volume":"49","author":"K Charalabopoulos","year":"2003","unstructured":"Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N. Penetration of antimicrobial agents into the prostate. Chemotherapy. 2003;49:269\u201379.","journal-title":"Chemotherapy"},{"key":"1341_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00504","volume":"11","author":"S Xiong","year":"2020","unstructured":"Xiong S, Liu X, Deng W, Zhou Z, Li Y, Tu Y, et\u00a0al. Pharmacological interventions for bacterial prostatitis. Front Pharmacol. 2020;11:504.","journal-title":"Front Pharmacol"},{"key":"1341_CR10","doi-asserted-by":"crossref","unstructured":"Onita T, Ishihara N, Yano T. PK\/PD-guided strategies for appropriate antibiotic use in the era of antimicrobial resistance. 2025;14:92","DOI":"10.3390\/antibiotics14010092"},{"key":"1341_CR11","volume":"2013","author":"G Perletti","year":"2013","unstructured":"Perletti G, Marras E, Wagenlehner FM, Magri V. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev. 2013;2013:Cd009071.","journal-title":"Cochrane Database Syst Rev"},{"key":"1341_CR12","doi-asserted-by":"crossref","unstructured":"Trinchieri A, Abdelrahman KM, Bhatti KH, Bello JO, Das K, Gatsev O, et\u00a0al. Spectrum of causative pathogens and resistance rates to antibacterial agents in bacterial prostatitis. Diagnostics (Basel, Switzerland). 2021;11.","DOI":"10.3390\/diagnostics11081333"},{"key":"1341_CR13","unstructured":"Davis NG, Silberman M. Acute Bacterial Prostatitis. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Michael Silberman declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2025, StatPearls Publishing LLC.; 2025"},{"key":"1341_CR14","volume":"13","author":"AS Khattak","year":"2021","unstructured":"Khattak AS, Raison N, Hawazie A, Khan A, Brunckhorst O, Ahmed K. Contemporary management of chronic prostatitis. Cureus. 2021;13:e20243.","journal-title":"Cureus"},{"issue":"Suppl 1","key":"1341_CR15","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/j.ijantimicag.2007.08.028","volume":"31","author":"JN Krieger","year":"2008","unstructured":"Krieger JN, Lee SW, Jeon J, Cheah PY, Liong ML, Riley DE. Epidemiology of prostatitis. Int J Antimicrob Agents. 2008;31(Suppl 1):S85-90.","journal-title":"Int J Antimicrob Agents"},{"key":"1341_CR16","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1177\/014556139407301207","volume":"73","author":"RA Otto","year":"1994","unstructured":"Otto RA, Noorily AD. Cephalosporin antibiotics. Ear, Nose, & Throat J. 1994;73:900.","journal-title":"Ear, Nose, & Throat J"},{"issue":"1","key":"1341_CR17","first-page":"22","volume":"12","author":"A Sobels","year":"2022","unstructured":"Sobels A, Lentjes KJ, Froeling F, van Nieuwkoop C, Wilms EB. Serum and prostatic tissue concentrations of cefazolin, ciprofloxacin and fosfomycin after prophylactic use for transurethral resection of the prostate. Antibiotics (Basel, Switzerland). 2022;12(1):22.","journal-title":"Antibiotics (Basel, Switzerland)."},{"key":"1341_CR18","doi-asserted-by":"crossref","unstructured":"Kuiper SG, Ploeger M, Wilms EB, van Dijk MM, Leegwater E, Huis In\u2019t Veld RAG, et\u00a0al. Ceftriaxone for the Treatment of Chronic Bacterial Prostatitis: A Case Series and Literature Review. Antibiotics (Basel, Switzerland). 2022;11.","DOI":"10.3390\/antibiotics11010083"},{"issue":"10","key":"1341_CR19","first-page":"940","volume":"13","author":"PJ Spachmann","year":"2024","unstructured":"Spachmann PJ, Fischer SE, Go\u00dfler C, Denzinger S, Burger M, Breyer J, et\u00a0al. Amoxicillin\/clavulanic acid in transrectal biopsy of the prostate-an alternative in times of ciprofloxacin obsolescence and fosfomycin limitation? Antibiotics (Basel, Switzerland). 2024;13(10):940.","journal-title":"Antibiotics (Basel, Switzerland)."},{"key":"1341_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-023-01391-7","volume":"23","author":"HY Kim","year":"2023","unstructured":"Kim HY, Lim D, Choi YH, Yoo JM, Lee DS, Lee SJ. Efficacy of fosfomycin compared to second generation cephalosporin flumarin as antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: a single center retrospective study. BMC Urol. 2023;23:211.","journal-title":"BMC Urol"},{"key":"1341_CR21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/0090-4295(76)90188-6","volume":"7","author":"AS Litvak","year":"1976","unstructured":"Litvak AS, Franks CD, Vaught SK, McRoberts JW. Cefazolin and cephalexin levels in prostatic tissue and sera. Urology. 1976;7:497\u20139.","journal-title":"Urology"},{"key":"1341_CR22","first-page":"410","volume":"35","author":"D Melloni","year":"1989","unstructured":"Melloni D, Ammatuna P, Formica P, Falletta V, Gaglio F, Cacciatore M, et\u00a0al. Pharmacokinetic study on adenomatous prostate tissue concentrations of cefoperazone. Clinical efficacy and patient tolerance of intramuscular cefoperazone treatment of chronic bacterial prostatitis. Chemotherapy. 1989;35:410\u20135.","journal-title":"Chemotherapy."},{"issue":"Suppl C","key":"1341_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/jac\/11.suppl_C.17","volume":"11","author":"KG Naber","year":"1983","unstructured":"Naber KG, Adam D. Tissue concentrations of mezlocillin in benign hypertrophy of the prostate following intravenous bolus injection versus infusion. J Antimicrob Chemother. 1983;11(Suppl C):17\u201323.","journal-title":"J Antimicrob Chemother"},{"key":"1341_CR24","first-page":"267","volume":"34","author":"RP Smith","year":"1988","unstructured":"Smith RP, Wilbur HJ, Bassey C, Baltch AL. Azlocillin and mezlocillin concentration in human prostatic tissue. Chemotherapy. 1988;34:267\u201371.","journal-title":"Chemotherapy"},{"key":"1341_CR25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/jac\/16.6.773","volume":"16","author":"JA Hoogkamp-Korstanje","year":"1985","unstructured":"Hoogkamp-Korstanje JA, de Leur EJ, Franssens D. The influence of prophylactic piperacillin on the postoperative course of transurethral prostatectomy. J Antimicrob Chemother. 1985;16:773\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"1341_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ijantimicag.2016.04.027","volume":"48","author":"C Dariane","year":"2016","unstructured":"Dariane C, Amin A, Lortholary O, Lalli A, Michel C, Le Guilchet T, et\u00a0al. Plasma and intraprostatic concentrations of ertapenem following preoperative single dose administration: a single-centre prospective experience and clinical implications-the ERTAPRO study. Int J Antimicrob Agents. 2016;48:168\u201374.","journal-title":"Int J Antimicrob Agents"},{"key":"1341_CR27","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1046\/j.1464-410X.1997.00146.x","volume":"79","author":"JC Png","year":"1997","unstructured":"Png JC, Tan E, Foo KT, Li MK, Cheng C, Rekhraj IR. A comparative study of the distribution of ofloxacin and ciprofloxacin in prostatic tissues after simultaneous oral ingestion. Br J Urol. 1997;79:781\u20134.","journal-title":"Br J Urol"},{"key":"1341_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1179\/joc.2008.20.2.213","volume":"20","author":"J Lugg","year":"2008","unstructured":"Lugg J, Lettieri J, Stass H, Agarwal V. Determination of the concentration of ciprofloxacin in prostate tissue following administration of a single, 1000 mg, extended-release dose. J Chemother. 2008;20:213\u20138.","journal-title":"J Chemother"},{"key":"1341_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S0140-6736(83)90258-1","volume":"2","author":"M Bologna","year":"1983","unstructured":"Bologna M, Vaggi L, Forchetti CM, Martini E. Bactericidal intraprostatic concentrations of norfloxacin. Lancet. 1983;2:280.","journal-title":"Lancet"},{"key":"1341_CR30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1128\/AAC.28.2.349","volume":"28","author":"MG Bergeron","year":"1985","unstructured":"Bergeron MG, Thabet M, Roy R, Lessard C, Foucault P. Norfloxacin penetration into human renal and prostatic tissues. Antimicrob Agents Chemother. 1985;28:349\u201350.","journal-title":"Antimicrob Agents Chemother"},{"key":"1341_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/BF02583030","volume":"20","author":"NR Netto Jr.","year":"1988","unstructured":"Netto NR Jr., Palma PC, Srulzon GB, Cortado PL, Fonseca RC. Concentrations of norfloxacin in prostatic tissues following oral administration in patients with benign prostatic hyperplasia. Int Urol Nephrol. 1988;20:47\u20139.","journal-title":"Int Urol Nephrol"},{"key":"1341_CR32","first-page":"240","volume":"33","author":"M Dan","year":"1987","unstructured":"Dan M, Golomb J, Gorea A, Lindner A, Berger SA. Penetration of norfloxacin into human prostatic tissue following single-dose oral administration. Chemotherapy. 1987;33:240\u20132.","journal-title":"Chemotherapy"},{"key":"1341_CR33","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/S0022-5347(17)42875-8","volume":"139","author":"KM Desai","year":"1988","unstructured":"Desai KM, Abrams PH, White LO. A double-blind comparative trial of short-term orally administered enoxacin in the prevention of urinary infection after elective transurethral prostatectomy: a clinical and pharmacokinetic study. J Urol. 1988;139:1232\u20134.","journal-title":"J Urol"},{"key":"1341_CR34","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1128\/AAC.32.9.1433","volume":"32","author":"MG Bergeron","year":"1988","unstructured":"Bergeron MG, Roy R, Lessard C, Foucault P. Enoxacin penetration into human prostatic tissue. Antimicrob Agents Chemother. 1988;32:1433\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"1341_CR35","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000464050","volume":"17","author":"M Charton","year":"1990","unstructured":"Charton M, Timbal Y. In vivo diffusion of enoxacin in healthy renal and adenomatous prostate tissue in man. Eur Urol. 1990;17:252\u20136.","journal-title":"Eur Urol"},{"key":"1341_CR36","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/jac\/46.6.993","volume":"46","author":"B Hamel","year":"2000","unstructured":"Hamel B, Mottet N, Audran M, Costa P, Bressolle F. Pharmacokinetics of enoxacin and its oxometabolite after multiple oral dosing and penetration into prostatic tissue. J Antimicrob Chemother. 2000;46:993\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"1341_CR37","first-page":"548","volume":"100","author":"J Chen","year":"2001","unstructured":"Chen J, Chen RR, Huang HS. Comparison of ofloxacin and norfloxacin concentration in prostatic tissues in patients undergoing transurethral resection of the prostate. J Formos Med Assoc. 2001;100:548\u201352.","journal-title":"J Formos Med Assoc"},{"key":"1341_CR38","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1128\/AAC.34.12.2398","volume":"34","author":"JM Kovarik","year":"1990","unstructured":"Kovarik JM, de Hond JA, Hoepelman IM, Boon T, Verhoef J. Intraprostatic distribution of lomefloxacin following multiple-dose administration. Antimicrob Agents Chemother. 1990;34:2398\u2013401.","journal-title":"Antimicrob Agents Chemother"},{"key":"1341_CR39","doi-asserted-by":"publisher","first-page":"121s","DOI":"10.1016\/0002-9343(92)90323-4","volume":"92","author":"IW Klimberg","year":"1992","unstructured":"Klimberg IW, Childs SJ, Madore RJ, Klimberg SR. A multicenter comparison of oral lomefloxacin versus parenteral cefotaxime as prophylactic agents in transurethral surgery. Am J Med. 1992;92:121s-s125.","journal-title":"Am J Med"},{"issue":"Suppl E","key":"1341_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jac\/31.suppl_E.39","volume":"31","author":"G Foulds","year":"1993","unstructured":"Foulds G, Johnson RB. Selection of dose regimens of azithromycin. J Antimicrob Chemother. 1993;31(Suppl E):39\u201350.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl A","key":"1341_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/jac\/25.suppl_A.73","volume":"25","author":"G Foulds","year":"1990","unstructured":"Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990;25(Suppl A):73\u201382.","journal-title":"J Antimicrob Chemother"},{"key":"1341_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00005392-200101000-00024","volume":"165","author":"A Giannopoulos","year":"2001","unstructured":"Giannopoulos A, Koratzanis G, Giamarellos-Bourboulis EJ, Panou C, Adamakis I, Giamarellou H. Pharmacokinetics of clarithromycin in the prostate: implications for the treatment of chronic abacterial prostatitis. J Urol. 2001;165:97\u20139.","journal-title":"J Urol"},{"key":"1341_CR43","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0090-4295(79)90376-5","volume":"13","author":"CB Williams","year":"1979","unstructured":"Williams CB, Litvak AS, McRoberts JW. Comparison of serum and prostatic levels of tobramycin. Urology. 1979;13:589\u201391.","journal-title":"Urology"},{"key":"1341_CR44","first-page":"511","volume":"32","author":"R Bismuth","year":"1984","unstructured":"Bismuth R, Fredj G, Khoury S, Rigat B. [Comparison of serum and prostatic levels of tobramycin]. Pathol Biol Paris. 1984;32:511\u20135.","journal-title":"Pathol Biol Paris"},{"key":"1341_CR45","first-page":"22","volume":"112","author":"EM Meares","year":"1975","unstructured":"Meares EM. Long-term therapy of chronic bacterial prostatitis with trimethoprim\u2013sulfamethoxazole. Can Med Assoc J. 1975;112:22\u20135.","journal-title":"Can Med Assoc J"},{"issue":"Suppl 4","key":"1341_CR46","doi-asserted-by":"publisher","first-page":"S330","DOI":"10.1007\/BF01639009","volume":"7","author":"DS Reeves","year":"1979","unstructured":"Reeves DS, Wilkinson PJ. The pharmacokinetics of trimethoprim and trimethoprim\/sulphonamide combinations, including penetration into body tissues. Infection. 1979;7(Suppl 4):S330\u201341.","journal-title":"Infection"},{"key":"1341_CR47","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1464-410X.1982.tb13588.x","volume":"54","author":"WL Wright","year":"1982","unstructured":"Wright WL, Larking P, Lovell-Smith CJ. Concentrations of trimethoprim and sulphamethoxazole in the human prostate gland after intramuscular injection. Br J Urol. 1982;54:550\u20131.","journal-title":"Br J Urol"},{"key":"1341_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1464-410X.1976.tb02748.x","volume":"48","author":"NF Dabhoiwala","year":"1976","unstructured":"Dabhoiwala NF, Bye A, Claridge M. A study of concentrations of trimethoprim-sulphamethoxazole in the human prostate gland. Br J Urol. 1976;48:77\u201381.","journal-title":"Br J Urol"},{"key":"1341_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0090-4295(76)90339-3","volume":"8","author":"PO Madsen","year":"1976","unstructured":"Madsen PO, Kjaer TB, Baumueller A. Prostatic tissue and fluid concentrations of trimethoprim and sulfamethoxazole: experimental and clinical studies. Urology. 1976;8:129\u201332.","journal-title":"Urology"},{"key":"1341_CR50","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1464-410X.1975.tb03970.x","volume":"47","author":"W Oosterlinck","year":"1975","unstructured":"Oosterlinck W, Defoort R, Renders G. The concentration of sulphamethoxazole and trimethoprim in human prostate gland. Br J Urol. 1975;47:301\u20134.","journal-title":"Br J Urol"},{"key":"1341_CR51","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0022-5347(17)58122-7","volume":"118","author":"TW Hensle","year":"1977","unstructured":"Hensle TW, Prout GR Jr., Griffin P. Minocycline diffusion into benign prostatic hyperplasia. J Urol. 1977;118:609\u201311.","journal-title":"J Urol"},{"key":"1341_CR52","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1093\/cid\/cit704","volume":"58","author":"BJ Gardiner","year":"2014","unstructured":"Gardiner BJ, Mahony AA, Ellis AG, Lawrentschuk N, Bolton DM, Zeglinski PT, et\u00a0al. Is fosfomycin a potential treatment alternative for multidrug-resistant Gram-negative prostatitis? Clin Infect Dis. 2014;58:e101\u20135.","journal-title":"Clin Infect Dis"},{"key":"1341_CR53","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1442-2042.1998.tb00597.x","volume":"5","author":"T Goto","year":"1998","unstructured":"Goto T, Makinose S, Ohi Y, Yamauchi D, Kayajima T, Nagayama K, et\u00a0al. Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate. Int J Urol. 1998;5:243\u20136.","journal-title":"Int J Urol"},{"key":"1341_CR54","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/BF01962362","volume":"7","author":"A Dalhoff","year":"1988","unstructured":"Dalhoff A, Weidner W. Diffusion of ciprofloxacin into prostatic fluid. Eur J Clin Microbiol Infect Dis. 1988;7:438\u20139.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1341_CR55","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000329520","volume":"57","author":"JB Bulitta","year":"2011","unstructured":"Bulitta JB, Kinzig M, Naber CK, Wagenlehner FM, Sauber C, Landersdorfer CB, et\u00a0al. Population pharmacokinetics and penetration into prostatic, seminal, and vaginal fluid for ciprofloxacin, levofloxacin, and their combination. Chemotherapy. 2011;57:402\u201316.","journal-title":"Chemotherapy"},{"key":"1341_CR56","first-page":"13","volume":"31","author":"JB Boerema","year":"1985","unstructured":"Boerema JB, Dalhoff A, Debruyne FM. Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy. 1985;31:13\u20138.","journal-title":"Chemotherapy"},{"issue":"Suppl 1","key":"1341_CR57","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2165\/00003495-198700341-00011","volume":"34","author":"KG Naber","year":"1987","unstructured":"Naber KG, Adam D, Kees F. In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients. Drugs. 1987;34(Suppl 1):44\u201350.","journal-title":"Drugs"},{"key":"1341_CR58","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/BF01710740","volume":"21","author":"KG Naber","year":"1993","unstructured":"Naber KG, Kinzig M, S\u00f6rgel F, Weigel D. Penetration of ofloxacin into prostatic fluid, ejaculate and seminal fluid. Infection. 1993;21:98\u2013100.","journal-title":"Infection"},{"key":"1341_CR59","first-page":"437","volume":"34","author":"F Kees","year":"1988","unstructured":"Kees F, Naber KG, Schumacher H, Grobecker H. Penetration of fleroxacin into prostatic secretion and prostatic adenoma tissue. Chemotherapy. 1988;34:437\u201343.","journal-title":"Chemotherapy"},{"issue":"Suppl D","key":"1341_CR60","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/jac\/22.Supplement_D.199","volume":"22","author":"KG Naber","year":"1988","unstructured":"Naber KG, S\u00f6rgel F, Kees F, Schumacher H, Metz R, Grobecker H. In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. J Antimicrob Chemother. 1988;22(Suppl D):199\u2013207.","journal-title":"J Antimicrob Chemother"},{"key":"1341_CR61","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1128\/AAC.45.1.293-297.2001","volume":"45","author":"CK Naber","year":"2001","unstructured":"Naber CK, Steghafner M, Kinzig-Schippers M, Sauber C, S\u00f6rgel F, Stahlberg HJ, et\u00a0al. Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers. Antimicrob Agents Chemother. 2001;45:293\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"1341_CR62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijantimicag.2007.08.025","volume":"31","author":"FM Wagenlehner","year":"2008","unstructured":"Wagenlehner FM, Kees F, Weidner W, Wagenlehner C, Naber KG. Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers. Int J Antimicrob Agents. 2008;31:21\u20136.","journal-title":"Int J Antimicrob Agents"},{"key":"1341_CR63","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jiac.2019.08.019","volume":"26","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Ikawa K, Nishikawa G, Kobayashi I, Tobiume M, Sugie M, et\u00a0al. Clinical pharmacokinetics of flomoxef in prostate tissue and dosing considerations for prostatitis based on site-specific pharmacodynamic target attainment. J Infect Chemother. 2020;26:236\u201341.","journal-title":"J Infect Chemother"},{"key":"1341_CR64","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jiac.2017.08.005","volume":"23","author":"K Nakamura","year":"2017","unstructured":"Nakamura K, Ikawa K, Nishikawa G, Kobayashi I, Narushima M, Muramatsu H, et\u00a0al. Clinical pharmacokinetics and pharmacodynamic target attainment of pazufloxacin in prostate tissue: dosing considerations for prostatitis. J Infect Chemother. 2017;23:809\u201313.","journal-title":"J Infect Chemother"},{"key":"1341_CR65","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jiac.2015.04.015","volume":"21","author":"I Kobayashi","year":"2015","unstructured":"Kobayashi I, Ikawa K, Nakamura K, Nishikawa G, Kajikawa K, Yoshizawa T, et\u00a0al. Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics. J Infect Chemother. 2015;21:575\u201380.","journal-title":"J Infect Chemother"},{"key":"1341_CR66","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ijantimicag.2012.11.001","volume":"41","author":"G Nishikawa","year":"2013","unstructured":"Nishikawa G, Ikawa K, Nakamura K, Yamada Y, Zennami K, Mitsui K, et\u00a0al. Prostatic penetration of meropenem in humans, and dosage considerations for prostatitis based on a site-specific pharmacokinetic\/pharmacodynamic evaluation. Int J Antimicrob Agents. 2013;41:267\u201371.","journal-title":"Int J Antimicrob Agents"},{"key":"1341_CR67","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1179\/1120009X12Z.0000000007","volume":"24","author":"K Nakamura","year":"2012","unstructured":"Nakamura K, Ikawa K, Yamada Y, Arakawa M, Zennami K, Nishikawa G, et\u00a0al. Determination of doripenem penetration into human prostate tissue and assessment of dosing regimens for prostatitis based on site-specific pharmacokinetic\u2013pharmacodynamic evaluation. J Chemother (Florence, Italy). 2012;24:32\u20137.","journal-title":"J Chemother (Florence, Italy)"},{"key":"1341_CR68","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.eururo.2024.03.035","volume":"86","author":"J Kranz","year":"2024","unstructured":"Kranz J, Bartoletti R, Bruy\u00e8re F, Cai T, Geerlings S, K\u00f6ves B, et\u00a0al. European Association of Urology guidelines on urological infections: summary of the 2024 guidelines. Eur Urol. 2024;86:27\u201341.","journal-title":"Eur Urol"},{"key":"1341_CR69","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.3892\/etm.2016.3631","volume":"12","author":"V Magri","year":"2016","unstructured":"Magri V, Montanari E, Marras E, Perletti G. Aminoglycoside antibiotics for NIH category II chronic bacterial prostatitis: a single-cohort study with one-year follow-up. Exp Ther Med. 2016;12:2585\u201393.","journal-title":"Exp Ther Med"},{"key":"1341_CR70","unstructured":"Block M, Blanchard DL. Aminoglycosides. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Dana Blanchard declares no relevant financial relationships with ineligible companies.: StatPearls Publishing"},{"key":"1341_CR71","first-page":"1035","volume":"4","author":"G Perletti","year":"2011","unstructured":"Perletti G, Skerk V, Magri V, Markotic A, Mazzoli S, Parnham MJ, et\u00a0al. Macrolides for the treatment of chronic bacterial prostatitis: an effective application of their unique pharmacokinetic and pharmacodynamic profile (Review). Mol Med Rep. 2011;4:1035\u201344.","journal-title":"Mol Med Rep"},{"key":"1341_CR72","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/aja.2011.36","volume":"13","author":"V Magri","year":"2011","unstructured":"Magri V, Montanari E, \u0160kerk V, Markoti\u0107 A, Marras E, Restelli A, et\u00a0al. Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction. Asian J Androlo. 2011;13:819\u201327.","journal-title":"Asian J Androlo"},{"key":"1341_CR73","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4081\/aiua.2018.4.227","volume":"90","author":"V Magri","year":"2019","unstructured":"Magri V, Boltri M, Cai T, Colombo R, Cuzzocrea S, De Visschere P, et\u00a0al. Multidisciplinary approach to prostatitis. Arch Ital Urol Androl. 2019;90:227\u201348.","journal-title":"Arch Ital Urol Androl"},{"key":"1341_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2005.04.013","volume":"26","author":"FM Wagenlehner","year":"2005","unstructured":"Wagenlehner FM, Weidner W, S\u00f6rgel F, Naber KG. The role of antibiotics in chronic bacterial prostatitis. Int J Antimicrob Agents. 2005;26:1\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"1341_CR75","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1586\/14787210.1.2.275","volume":"1","author":"FM Wagenlehner","year":"2003","unstructured":"Wagenlehner FM, Naber KG. Antimicrobial treatment of prostatitis. Expert Rev Anti Infect Ther. 2003;1:275\u201382.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1341_CR76","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1128\/AAC.01884-13","volume":"58","author":"FK Hurtado","year":"2014","unstructured":"Hurtado FK, Weber B, Derendorf H, Hochhaus G, Dalla Costa T. Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis. Antimicrob Agents Chemother. 2014;58:678\u201386.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 7A","key":"1341_CR77","doi-asserted-by":"publisher","first-page":"7s","DOI":"10.1016\/j.amjmed.2005.05.008","volume":"118","author":"RD David","year":"2005","unstructured":"David RD, DeBlieux PM, Press R. Rational antibiotic treatment of outpatient genitourinary infections in a changing environment. Am J Med. 2005;118(Suppl 7A):7s\u201313s.","journal-title":"Am J Med"},{"key":"1341_CR78","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf250","volume":"8","author":"E Lecomte","year":"2026","unstructured":"Lecomte E, Arys M, Christiaens A, Doyen L, Marot JC, Verbelen V, et\u00a0al. Prioritizing cefuroxime as empirical treatment in acute bacterial prostatitis: patient characteristics and outcome. JAC-Antimicrob Resist. 2026;8:dlaf250.","journal-title":"JAC-Antimicrob Resist."},{"key":"1341_CR79","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.euf.2023.07.006","volume":"10","author":"K Bausch","year":"2024","unstructured":"Bausch K, Mantica G, Smith EJ, Bartoletti R, Bruy\u00e8re F, Cai T, et\u00a0al. Genitourinary tuberculosis: a brief manual for urologists on diagnosis and treatment from the European Association of Urology Urological Infections Panel. Eur Urol Focus. 2024;10:77\u20139.","journal-title":"Eur Urol Focus"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01341-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01341-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01341-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T18:01:53Z","timestamp":1786557713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01341-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1341"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01341-4","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Rui Ge has nothing to disclose. Xinwen Nian has nothing to disclose. Benjuan Liu has nothing to disclose. Yunyun Yang has nothing to disclose. Zhuo Wang has nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}